| Market Cap | 32.52M | P/E | - | EPS this Y | 28.10% | Ern Qtrly Grth | - |
| Income | -19.02M | Forward P/E | -2.74 | EPS next Y | 14.10% | 50D Avg Chg | -8.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 3.00% |
| Dividend | N/A | Price/Book | 2.37 | EPS next 5Y | - | 52W High Chg | -39.00% |
| Recommedations | 2.00 | Quick Ratio | 6.65 | Shares Outstanding | 27.45M | 52W Low Chg | 194.00% |
| Insider Own | 40.18% | ROA | -56.85% | Shares Float | 14.50M | Beta | 0.17 |
| Inst Own | 17.86% | ROE | -103.81% | Shares Shorted/Prior | 479.69K/568.37K | Price | 2.00 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 257,740 | Target Price | 7.00 |
| Oper. Margin | - | Earnings Date | Nov 9 | Volume | 49,984 | Change | -2.44% |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
| HC Wainwright & Co. | Buy | Aug 19, 24 |
| HC Wainwright & Co. | Buy | Jul 26, 24 |
| HC Wainwright & Co. | Buy | Jul 9, 24 |
| HC Wainwright & Co. | Buy | Jul 1, 24 |
| Roth MKM | Buy | Aug 14, 23 |
| Roth MKM | Buy | Feb 22, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hsu Jason | Director Director | Dec 08 | Buy | 4.78 | 56,000 | 267,680 | 813,000 | 12/12/23 |
| Hsu Jason | Director Director | Sep 11 | Buy | 2.7 | 72,000 | 194,400 | 757,000 | 09/18/23 |
| Ng Carey | Director Director | Sep 14 | Buy | 2.576 | 10,000 | 25,760 | 10,000 | 09/15/23 |
| Adams Helen C. | Director Director | Sep 12 | Buy | 2.9609 | 13,000 | 38,492 | 13,000 | 09/14/23 |
| Hsu Jason | Director Director | Sep 08 | Buy | 2.5317 | 10,000 | 25,317 | 685,000 | 09/12/23 |
| BUCHAN MELISSA JANE | Director Director | Sep 07 | Buy | 2.4613 | 20,000 | 49,226 | 20,000 | 09/11/23 |
| Marquet Magda | Director Director | Sep 06 | Buy | 2.4681 | 9,000 | 22,213 | 20,000 | 09/08/23 |
| Marquet Magda | Director Director | Aug 31 | Buy | 2.01 | 1,000 | 2,010 | 1,000 | 09/05/23 |
| Senn Sean | 10% Owner 10% Owner | Jul 14 | Sell | 2.75 | 200 | 550 | 899,800 | 07/18/22 |